Table 1.
Active Phase 3 clinical trials of pharmacological treatments in AD (clinicaltrials.gov as of February 10, 2021)
| Investigational drug | Study population/treatment target | Type of treatment | Clinical trial identifier |
|---|---|---|---|
| Disease modifying treatment | |||
| Gantenerumab | prodromal to mild AD | fully human monoclonal antibody |
NCT03443973 NCT03444870 NCT02051608 NCT01224106 |
| Solanezumab | asymptomatic AD, positive amyloid PET | humanized monoclonal antibody | NCT02008357 |
| Aducanumab | prodromal to mild AD, previous participants in aducanumab clinical study | fully human monoclonal antibody | NCT04241068 |
| Lecanemab (BAN2401) | prodromal to mild AD | humanized monoclonal antibody |
NCT03887455 NCT04468659 |
| TRx0237 (Methylene blue) | MCI and probable AD, positive amyloid PET | tau aggregation inhibitor | NCT03446001 |
| AGB101 (Levetiracetam) | prodromal AD | anticonvulsant, SV2A modulator | NCT03486938 |
| BHV-4157 (Riluzole prodrug) | mild to moderate AD | glutamate release inhibitor | NCT03605667 |
| ALZT-OP1 (cromolyn+ibuprofen) | prodromal AD | mast cell stabilizer, microglial modulator, anti-inflammatory | NCT02547818 |
| Sodium Oligomannate (GV-971) | mild to moderate AD | bioactive marine-derived oligosaccharide | NCT04520412 |
| Tricaprilin | mild to moderate AD | inductor of ketosis | NCT04187547 |
| NE3107 | mild to moderate AD | sterol derivative | NCT04669028 |
| COR388 | mild to moderate AD | gingipains inhibitor | NCT03823404 |
| Preventional treatment | |||
| CAD106 | elderly homozygous ApoE4 carriers at risk of clinical AD | anti-Aβ vaccine + BACE1 inhibitor | NCT02565511 |
| Solenezumab | individuals at risk due to AD-causing mutations | monoclonal Aβ antibodies | NCT01760005 |
| Metformin | early and late MCI | antihyperglycemic agent | NCT04098666 |
| Symptomatic treatment | |||
| Brexpiprazole | agitation due to AD | dopamine D2 receptors partial agonist |
NCT03594123 NCT03724942 NCT03548584 NCT03620981 |
| AVP-786 | agitation due to AD | NMDA receptors antagonist and sigma 1 receptors agonist |
NCT03393520 NCT02446132 |
| Escitalopram | agitation due to AD | selective serotonin reuptake inhibitor | NCT03108846 |
| Mirtazapine | agitation due to AD | adrenergic α2 and serotonin 5-HT2/5-HT3 receptors antagonist | NCT03031184 |
| Nabilone | agitation due to AD | synthetic cannabinoid | NCT04516057 |
| Octohydroaminoacridine succinate | cognitive deficiencies in mild to moderate AD | acetylcholinesterase inhibitor | NCT03283059 |
| ANAVEX2–73 | cognitive deficiencies in prodromal AD | Sigma1 receptor agonist | NCT03790709 |
| Guanfacine | attention deficit in AD | adrenergic α2 receptors agonist | NCT03116126 |
| Methylphenidate | apathy in AD | dopamine and norepinephrine reuptake inhibitor | NCT02346201 |